European evidence-based Consensus on the management of ulcerative colitis: Current management

TLDR

Ulcerative colitis management prioritizes disease activity, extent, relapse frequency, prior treatment response, side‑effect profile, and extra‑intestinal manifestations, with severity distinguished by the Truelove & Witts index that identifies severe cases requiring hospitalization. The consensus recommends confirming active disease with sigmoidoscopy or proctoscopy and actively involving patients in treatment decisions. The guideline advocates rectal mucosal biopsy to rule out alternative causes such as infections or Crohn’s disease. The Truelove & Witts index, employed in 20 of 32 studies on intensive IV therapy, reliably distinguishes severe from moderate or mild ulcerative colitis despite its unresponsive nature.

Abstract

### 5.1 General The general principles for treating active ulcerative colitis are to consider the activity, distribution (proctitis, left-sided, extensive,1 and pattern of disease (relapse frequency, course of disease, response to previous medications, side-effect profile of medication, extra-intestinal manifestation), before treatment decisions are made in conjunction with the patient. #### 5.1.1 Disease activity The principal scoring systems used for clinical trials are covered in Section 5.1.2 and have been comprehensively reviewed.2 Some additional points are clinically relevant. In clinical practice it matters most to distinguish severe ulcerative colitis necessitating hospital admission from those with mild or moderate disease who can generally be treated as outpatients. The simplest, best validated and most widely used index for identifying acute severe UC remains that of Truelove & Wi_tts 3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3). This index has been used in 20/32 studies of intensive intravenous treatment for severe UC.4 Only one additional criterion in addition to the bloody stool frequency ≥ 6/day is needed to define a severe attack.5 While these criteria have the major limitation of being unresponsive and cannot track the course of disease, they do distinguish the severe from the moderate or mild and have value in everyday practice because they are easy to use, which no other index achieves. It should be standard practice to confirm active colitis by sigmoidoscopy or proctoscopy before starting treatment. Rectal mucosal biopsy helps exclude unexpected causes of symptoms similar to active disease (such as cytomegalovirus, amoebic, or other infection, rectal mucosal prolapse, Crohn's disease, or even irritable bowel syndrome and haemorrhoidal bleeding). #### 5.1.2 Approach Patients should be encouraged to participate actively in …